Aberrant activation of the NF-B transcription factors underlies chemoresistance in various cancer types including colorectal cancer (CRC). Targeting the activating mechanisms, particularly with inhibitors to the upstream IB kinase (IKK) complex, is a promising strategy to augment the effect of chemotherapy.
INTRODUCTION
The incidence of colorectal cancer (CRC) is rising worldwide (1, 2) . Systemic chemotherapy is critical in improving survival, but clinical response is highly variable (3) . Increased efflux, decreased uptake and impairment in enzymatic conversion to active metabolites are strategies utilized by CRC cells to lower the effective intracellular concentrations of chemotherapeutics, but these can be partly overcome by combining different chemotherapeutic agents. However, enhanced survival mechanism driven by NF-B, MAPK, -catenin, TNF or PI3K pathways, poses an additional therapeutic barrier (4, 5) . Of these, the NF-B pathway is one of the best characterized. High basal tumor NF-B expression is present in at least 40% of CRC tumor samples and is associated with aggressive phenotype and resistance to chemotherapy (6) (7) (8) (9) . Genetic ablation of IB kinase -isoform (IKK), the master kinase within the IKK complex that activates the canonical NF-B transcription factors, in intestinal epithelium significantly reduced colitis-induced CRC in mice (10) . Besides basal level, NF-B activity in CRC cells can be further induced upon exposure to chemotherapy (7, 11) . Therefore there is strong rationale for targeting the NF-B pathway in CRC, particularly through inhibiting the IKK complex (12) . Unfortunately, success has been limited to date, as most of the tested inhibitors lack specificity and/or are highly toxic, as reflected by embryonic lethality of ablating IKK or RelA in mice (13) (14) (15) (16) . Therefore, novel, less toxic approaches to target the NF-B pathway should be explored.
In epithelial cells, the IKK-NF-B axis can be activated by the Toll/IL-1R (TIR) superfamily members, which consist of the Toll-like (TLRs) and IL-1 (IL-1R) families of receptors (17) . Ligation of these receptors result in recruitment and assembly of the adaptor protein MyD88 and Interleukin-1 Receptor-associated kinase (IRAK) isoforms 1, 2 and 4, leading to activation of TAK1 kinase and subsequently the IKK complex and NF-B (18) . Therapeutic value for targeting the IRAK members, specifically the IRAK1 and IRAK4 isoforms, has been elucidated in several cancer types including diffuse large B cell lymphoma (DLBCL) (19, 20) , myelodysplastic syndrome (21) , T-cell ALL (22) , melanoma (23) , breast cancer (24) , head and neck cancer (25) , and in pancreatic cancer by our group (26, 27) . In pancreatic cancer, IL-1 secreted by both neoplastic cells and fibroblasts activate the IRAK4-NF-B axis to foster tumor fibrosis, which contributes to chemoresistance. Notably, we showed that the kinase activity of IRAK4, but not IRAK1, is essential in driving NF-B activity in pancreatic cancer cells (27) . Contribution of the TIR receptors and IRAK4 in the progression and treatment resistance of CRC has not been investigated in detail. In an elegant study, KRAS-dependent colon cancer cells stimulates BMP-7 secretion to autologously activate BMP receptor, TAK1 kinase and the NF-B transcription factors (28) . To date, safe and effective TAK1 inhibitors remain elusive. TAK1 deletion leads to massive bone marrow and liver failure in mice, again raising concerns for toxicities associated with TAK1 inhibitors (29) . Contrastingly, an IRAK4 inhibitor is currently being tested in a clinical trial (NCT03328078) for refractory DLBCL. In this study, we investigated whether IRAK4 is activated, has a pathogenic role, and is a good therapeutic target in CRC.
RESULTS

IRAK4 is required for colitis-induced neoplasm in APC
Min/+ mice.
We observed robust phosphorylated (denoted p-) IRAK4, p65 and p50 NF-B subunit staining by immunohistochemistry (IHC) in colon cancer spontaneously formed in APC Min/+ mice, whereas these markers were absent or very faint in normal colon epithelium in age-matched wild-type littermates ( Figure   1A ). While APC Min/+ mice formed almost exclusively small intestinal tumors, treatment with 2% dextran sodium sulfate (DSS) in drinking water induces colitis and development of colonic neoplasm at very high penetrance (30) , and is a robust model for studying colon cancer progression. Using this approach, we found that mice pre-treated with DSS followed by an IRAK4 inhibitor (IRAK4i) PF06650833 developed significantly fewer visible tumors and microadenomas compared to vehicle-treated mice, and the number of neoplasms in either gender was similar in both treatment groups ( Figure 1B, 1C) . Intensities of p-IRAK4 and p-p65 IHC staining were drastically diminished in IRAK4i-treated colon, indicating on-target effect of PF06650833 (Supplementary Figure 1) . Notably, focused analyses on microadenomas showed that IRAK4i-treated tumors contained significantly less proliferating neoplastic (dual CK + Ki-67 + ) cells ( Figure 1D ). Importantly, IRAK4i protected mice from significant weight loss, with none of IRAK4i-treated mice reaching humane endpoint while many vehicle-treated mice had to be sacrificed ( Figure 1E Figure   2B ). Notably, mice transplanted with IRAK4-null bone marrow had significantly less degree of colitis, as scored based on crypt damage and inflammatory infiltrates ( Figure 2C ). These results suggest an essential role for IRAK4 function in hematopoietic cells in colitis-induced neoplastic transformation, reflecting the known role of IRAK4 in innate immunity (31) . Intriguingly, we did not observe statistically significant difference in the abundance of CD45 + leukocytes in the colon epithelium or tumors in either group ( Figure 2D ), strongly suggesting an essential role for IRAK4 in altering the composition, rather than quantity, of immune infiltrates that mediates colitis and neoplastic progression.
IRAK4 is constitutively activated and drives NF-B activity in human CRC.
We next evaluated activation status of the IRAKs and NF-B pathway proteins in human CRC. We detected robust p-IRAK1, a direct substrate of IRAK4, in 11 out of 12 CRC lines, whereas p-IRAK1 signals were faint in normal colon cell lines FHC and CCD-18Co. On the other hand, p-IRAK4 is detectable at various intensities in both normal and CRC lines ( Figure 3A ). In these CRC lines, we did not detect an N-terminally truncated, inactive form of IRAK4 protein using an antibody raised against the C-terminus of IRAK4, as reported in myeloid malignancies(32) (Supplementary Figure 2A) . Notably, p-IKK p-p65
and p-p50 are detected predominantly in CRC lines. In this limited panel of cell lines, we did not observe any correlation between known genetic mutations (KRAS, PIK3CA and BRAF) and activation status of these NF-B pathway molecules, indicating that NF-B activity cannot be contributed to these oncogenic events. Next, we performed IHC analyses using a pool of five commercial human CRC tissue microarrays (TMAs). We found p-IRAK4 IHC staining to be significantly stronger in CRC (N=220) compared to normal colon tissues (N=49, Figure 3B ), although a fraction of normal colon mucosa also stained robustly with p-IRAK4. The staining intensity of p-IRAK4 did not differ among CRC from various clinical stage (Supplementary Figure 2B) . Perhaps relevant, expression of IRAK4 mRNA is significantly higher in colon cancer than normal colon tissues from analysis of Oncomine(33), a public microarray database (Supplementary Figure 2C) . Upregulated p-IRAK4 staining was also present in benign colonic polyps, although the number of samples was low (N=10). Interestingly, p-IRAK4 staining in tumor-adjacent normal colon samples was higher compared to non-cancerous colon samples. These results suggest that IRAK4 can be activated as early as pre-cancerous stage and participates in neoplastic progression, echoing our observation in APC Min/+ mice. Notably, we observed strong, significant correlation between the p-IRAK4 and p-p65 IHC staining in colon cancer samples ( Figure 3C ). We did not use p-p50 for correlation because the distribution of p-p50 is almost exclusively nuclear, precluding accurate interpretation of staining intensity. Together, these results establish strong correlation between activation of IRAK4 and NF-B pathway during CRC progression.
IRAK4 drives NF-B activity in human and murine CRC cells
To investigate the causal relationship between IRAK4 and NF-B activity, we stably silenced IRAK4 in two CRC lines, DLD-1 and KM12, using two different small hairpin RNAs (shRNAs). We observed Figure 3B) . Together, we conclude that IRAK4 is necessary for both the hematopoietic and epithelial compartments in CRC development and progression. Together, our results strongly support IRAK4 as the driver of the canonical NF-B pathway and is required for tumorigenesis of CRC cells.
IRAK4 Inhibitors suppress NF-B activity in CRC cells
To translate our findings, we tested two different IRAK4 inhibitors (IRAK4i). Of these, PF06650833 is being tested in clinical trial (35) , and was shown to protect inflammation-associated renal failure in rats (36) . We previously showed that AS2444697 blocks IL-1 induced NF-B activation in pancreatic cancer cells (27, 36) . Here, we observe varied susceptibility of different CRC lines to both IRAK4i in standard 2D cultures ( Figure 5A ). Importantly, we observed strong positive correlation in IC50 values between the two IRAK4i across 13 CRC lines, cross validating the specificity of these two compounds ( Figure 5B ). Supporting our results using shRNAs, both IRAK4i's suppressed clonogenic growth of CRC cells ( Figure 5C ). Notably, while IRAK4i did not suppress growth of SW80 and SW620 cells in monolayer culture, they potently suppressed clonogenic growth of these cells, implying engagement and need for IRAK4 and NF-B activation in stress-induced conditions, as we previously reported in pancreatic cancer cells (26) . Both IRAK4i potently blocked p-IRAK1, p-p50, nuclear translocation of p65 and NF-B driven luciferase reporter activity dose-dependently in CRC cells ( Figure 5D , 5E, 5F). Notably, PF06650833 was also able to dose-dependently suppress p-IRAK4 and p-IRAK1 in normal colon cell line FHC (Supplementary Figure 3C) , suggesting IRAK4 as the upstream activator of IRAK1 in non-neoplastic colon cells. As further validation of their specificity, the inhibitory effects of PF06650833 and AS2444697
on NF-B reporter can be completely abolished by ectopic expression of constitutively active IKK mutant(37), but not wild-type IKK ( Figure 5G ). These results validate the utility of these IRAK4
inhibitors as NF-B suppressors in CRC.
Chemotherapy induces TLR9-IRAK4 circuitry to sustain CRC cell survival
Besides basal activity, DNA damage such as that induced by chemotherapy can activate ATM, which can bind and activate TAK1 and IKK (NEMO) subunit, resulting in further activation of the canonical NF-B cascade which allows cells to survive and undergo DNA repair (38) . Therefore, abrogating NF-B induction represents a promising strategy to potentiate the cytotoxic effect of chemotherapy (39) . As expected, we found that exposure of CRC cells to chemotherapy significantly upregulates NF-B reporter activity in CRC cells ( Figure 6A ). While oxaliplatin and 5-FU alone were able to modestly activate NF-B activity, the combination of both agents led to a more significant upregulation, indicating that the degree of NF-B induction is not specific to any class of chemotherapeutic but is more likely associated with the extent of DNA damage. To explore whether IRAK4 is required for chemotherapy-induced NF-B Because TLR9 is known to sense double-stranded DNAs, which presumably are enriched following DNA damage, these data depict a scenario where damaged DNA may bind and activate TLR9, leading to IRAK4-IKK-NF-B activation which in turn further upregulates TLR9 expression, forming a feedforward circuitry to sustain cellular survival. Therefore, breaking this circuitry with IRAK4i or IMD0354 can enhance the pro-apoptotic effect of chemotherapy. Together, these results provide strong rationale for testing IRAK4 inhibitors in combination with chemotherapy in vivo.
IRAK4 inhibition synergizes with chemotherapy in vitro and in vivo
We next quantified the drug effect interactions between the two IRAK4 inhibitors and oxaliplatin, SN38
and 5-FU, across six fixed-ratio doses in three CRC cell lines, using the widely adopted Chou- Talalay we found that patients with high tumor p-IRAK4 IHC staining had significantly poorer overall survival compared with those with medium to low p-IRAK4 levels ( Figure 8G ). Overall, these data show that high IRAK4 activity is a poor prognostic factor for CRC patients, lending further support for targeting IRAK4 in combination with chemotherapy in CRC to improve outcome.
DISCUSSION
In the present study, we provided evidence, for the first time, that IRAK4 is activated and drives IKK-NF- inhibitors that we used had no single agent activity in CRC growth in vivo, indicating the need to combine with chemotherapy in future clinical trial design for CRC patients. In addition, all combo-treated mice eventually still succumbed to disease progression, suggesting emergence of resistance mechanisms which remain to be investigated. Importantly, because IRAK4-null mice are defective in mounting innate immunity when challenged with microbes(43), and IRAK4-deficient patients suffer from severe bacterial infections before puberty (44, 45) , infection will be a concern for IRAK4 inhibitors especially when coadministered with chemotherapy. Therefore, proper anti-microbial prophylaxis should be considered in future clinical trial design.
In this study, we showed TLR9 to be the driver of IRAK4 and NF-B in CRC cells upon chemotherapy exposure. Interestingly, we also observed significantly upregulated TLR9 mRNA expression in pancreatic cancer cells (MIA Paca-2) following exposure to oxaliplatin, SN38, 5-FU and gemcitabine, suggesting TLR9 upregulation may be a common adaptive response following DNA damage at least in these two cancer types (Supplementary Figure 7) . Based on these premises, we propose that acute DNA damage response recruits ATM, which directly triggers the NF-B cascade, while damaged DNA may also activate the preexisting pool of TLR9. Activation of the NF-B cascade results in transcriptional upregulation of TLR9, which subsequently engages the IRAK4-NF-B cascade to amplify and sustained the feedforward circuitry ( Figure 9 ). Besides TLR9, it is reasonable to hypothesize that one or more TLRs, and their natural ligands originating from surrounding damaged cells or even gut microbes within the tumor microenvironment, to be the trigger of IRAK4 and NF-B in CRC. Supporting this notion, manipulation of gut microbiome composition with fecal transfer or antibiotics can enhance or lower colitis-induced CRC formation in mice (46, 47) , establishing microbiota dysbiosis as a pro-tumorigenic event. More provocatively, transfer of fecal samples from CRC patients promotes intestinal inflammation and tumorigenesis in germ-free mice (48) . Because IRAK4 is the master kinase downstream of most TLRs, it will be very interesting to determine whether IRAK4 inhibition can suppress CRC formation in these models.
The actual role of MyD88, the critical adaptor that recruits and activate IRAK4, during different stages of colitis-induced CRC development is divergent, largely dependent on mouse models and experimental conditions (49) . We showed that IRAK4 inhibitor is highly effective in blocking DSS-induced neoplastic progression in APC Min/+ mice but has no effect on tumorigenic growth of established CRC tumors in vivo.
To clearly determine the role of epithelial IRAK4 during neoplastic progression, we pre-treated APC Lastly, we showed that activated IRAK4 (p-IRAK4) is associated with poor prognosis in CRC patients with Stage IIb-IV disease after resection. These patients are routinely treated with chemotherapy (mainly FOLFOX) following surgery and therefore high p-IRAK4 is a potential indicator for lack of benefit from chemotherapy. Our results are in congruent with another report which showed that overexpression of MyD88 is associated with poor prognosis in colon cancer (57) . Importantly, it is well-appreciated that only about 20% patients with Stage III CRC benefit from adjuvant FOLFOX (58) . While various combinations of markers have been developed to aid prognostication and patient selection for chemotherapy (59) , enhancing the effect of chemotherapy, as can be achieved by co-targeting IRAK4 and the IKK-NF-B, represents an equally important endeavor to improve overall patient outcome.
In summary, our study provides preclinical rationale for testing IRAK4 inhibitors in combination with chemotherapy in CRC. We demonstrate that chemotherapy can induce IKK-NF-B and sustain CRC cell survival by upregulating TLR9-IRAK4 signaling, providing justification for targeting IRAK4. Further work is needed to elucidate potential resistance mechanisms and to enable development of more effective and durable combinatorial regimens for this promising treatment paradigm.
METHODS
Cell lines.
All human cell lines were purchased from ATCC, which performs its own authentication by short tandem repeat DNA profiling. MC38 cell line was a kind gift from Dr. David DeNardo (WUSTL, St.
Louis) SW620, SW620-L1 and SW620-L2 were kind gifts from Dr. Mien-Chie Hung (MDACC, Houston), were published(60) and not further authenticated. All cells were cultured in DMEM/10% FBS/1% PenStrep at 5% CO2, 37°C incubators. Mycoplasma testing was performed every 6 months using MycoSEQ Detection kit (Applied Biosystems). All cell lines were used for fewer than 6 months after receipt or resuscitation from cryopreservation.
Human, murine CRC samples and Tissue Microarrays (TMA).
All studies were performed per ethical principles of both in Declaration of Helsinki. Commercial CRC TMA sections were purchased from US BioMax (C0702a, C0952a, BC05002b, BC051110b, HCol-Ade180Sur-08). All cases were de-identified. Plasmids and creation of stable cell lines. Stable knockdowns were generated using pSuperRetro as described (26) . Target sequences: shIRAK4#1: TTCAGTAGTAATGTCAACC ; shIRAK4#2:
GCCTAATGGTTCATTGCTA, shTLR9# GAGCTAAACCTGAGCTACAAC; shTLR9#2:
GCACGGTGCCACCTCCACACT. Mouse CRISPR sequences: sgIRAK4#1:
GTCGCCAACTGTGCAGTTCG; sgIRAK4#2: TGGCGACCTTGTGGATCTAC.
Drugs and reagents. 5-FU and oxaliplatin were purchased from the Siteman Cancer Center Pharmacy.
SN-38 was purchased from Pfizer. Details of inhibitors were: IRAK4 inhibitors PF06650833 (Tocris, cat#6373), AS2444697 (Tocris, cat#5430) andIMD-0354 (Tocris, cat#2611).
NF-B reporter assays. These were done using Dual-Glo® Luciferase Assay System and read with Synergy H4 Hybrid Microplate Reader.
Western blots. Cell lysates were harvested using radioimmunoprecipitation assay (RIPA) cell lysis buffer [10 mM Tris-HCl (pH 7.4), 50 mM NaCl, 0.05% sodium dodecyl sulfate, 10 mM Na2EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate), supplemented with protease and phosphatase inhibitors In vitro cell viability assay and calculation of combination indices. 5,000 cells/well were plated in triplicates in 96 well plates one day prior to addition of the inhibitors at the indicated final concentrations.
After 5 or 7 days of culture, viability assay was measured using Resazurin colorimetric analysis as described (26) . For drug interaction studies, cells were cultured in triplicates in the presence of six fixedratio concentrations for 72 hours followed by Alamar Blue viability assay. Combination indices were calculated using Compusyn software as described (41) . All experiments were done at least three times in triplicates and one most representative set of data was presented.
PLA (Proximal Ligation Assay)
PLA was performed using Duolink in situ starter kit (DUO92101, Sigma) per manufacturer's protocol.
Number of puncta per field was quantitated using NIS-element software using Nikon C2+ fluorescent confocal microscope. Ten random 400X fields per condition were analysed and quantitated. 
Statistics.
All results, when applicable, were expressed as the means ± SEM. Statistical analysis was performed using the Prism 6 software program. Unpaired student's two-tailed t-tests were used to compare two groups when appropriate. For multiple groups, one-way ANOVA analysis with Tukey's posttest were used. P values <0.05 were considered as statistically significant. Cox proportional hazards models were used to evaluate the relationships between clinical characteristics and overall survival. The upper quantile of p-IRAK4 H score in TMA and IRAK4 mRNA in TCGA are used as cut point. Survival probabilities were calculated using Kaplan-Meier method. Differences between strata of p-IRAK4 H score and IRAK4 mRNA were determined by log-rank tests. All statistical tests were two-sided using an α = 0.05 level of significance. SAS Version 9.4 (Cary, NC) was used to perform all survival analyses.
Study Approval
All mouse experiments were conducted under approval by WUSTL IACUC protocol (#20160142). We adhered to the ARRIVE guidelines for reporting on animal studies. All human tissue studies were approved by the Washington University School of Medicine Ethics Committee (IRB # 201108117). 
